Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, LEI Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2022) 140 (Supplement 1): 6554–6555.

https://doi.org/10.1182/blood-2022-165797

Published: 2022

Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Blood (2021) 138 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2021-145282

Published: 2021

Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Blood (2021) 138 (Supplement 1): 4778.

https://doi.org/10.1182/blood-2021-146784

Published: 2021

Journal Articles

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Huiqiang Huang, Yan Gao, Huilai Zhang, Keshu Zhou, Jianqiu Wu, Zhen Cai, Hongmei Jing, Lei Fan, Sai Lou, Yizhou Fei, Aihua Wang, Kevin Lynch

Blood (2021) 138 (Supplement 1): 2452.

https://doi.org/10.1182/blood-2021-147100

Published: 2021

Journal Articles

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Claire L Feerick, Kevin Lynch, Janusz Krawczyk, Michael O'Dwyer, Aideen Ryan

Blood (2021) 138 (Supplement 1): 2664.

https://doi.org/10.1182/blood-2021-152432

Published: 2021

Journal Articles

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Dawn Swan, Michael E. O'Dwyer, Mary Cahill, Janusz Krawczyk, Vitaliy Mykytiv, John Quinn, Robert Henderson, Cian McEllistrim, Andres Hernando, Imelda Parker, Marc Nolan, Elizabeth Lenihan, Eva Szegezdi, Serika D Naicker, Kevin Lynch, Alessandro Natoni, Aideen Ryan, Philip Murphy

Blood (2021) 138 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2021-145530

Published: 2021

Journal Articles

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

Kevin Lynch, BSc, MSc, O'Malley Grace, BSc, Aideen Ryan, BSc,PhD, Thomas Ritter, BSc, PhD, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 124.

https://doi.org/10.1182/blood.V130.Suppl_1.124.124

Published: 2017

Journal Articles

An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

Blood (2015) 126 (23): 710.

https://doi.org/10.1182/blood.V126.23.710.710

Published: 2015

Journal Articles

Identification of a Prognostic Gene Expression Signature for AZA Response in MDS and CMML Patients

Blood (2014) 124 (21): 4601.

https://doi.org/10.1182/blood.V124.21.4601.4601

Published: 2014

Journal Articles

Cord Blood Plasma Enhances Migration of Hematopoietic Stem and Progenitor Cells (HSPC)

James G Farmar, PhD, Alexander Wendling, B.Sc, Kevin Lynch, PhD, Jose Tomsig, MD, PhD, Mariusz Z Ratajczak, Hongyan Lu, PhD, Amandeep Salhotra, MD, Shicheng Yang, MD PhD, Xiao Huang, BSc, Harun El Masri, PhD, Mary J. Laughlin, MD

Blood (2011) 118 (21): 2959.

https://doi.org/10.1182/blood.V118.21.2959.2959

Published: 2011

Journal Articles

Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy

Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Peter C Gambell, Amanda Choo, Jennifer Curnow, MBBS, PhD, FRACP, FRCPA, Kevin Lynch, MBBS, Simon J. Harrison, MD, PhD, Hang Quach, David Ritchie, MBBS, FRACP, FRCPA, Miles Prince, MD, FRACP, FRCPA, David Alan A Westerman, MBBS, FRACP, FRCPA

Blood (2010) 116 (21): 3187.

https://doi.org/10.1182/blood.V116.21.3187.3187

Published: 2010

Journal Articles

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

David Alan Westerman, MBBS, FRACP, FRCPA, Giada Zapparoli, Chelsee Hewitt, Kevin Lynch, MBBS, Linda Mileshkin, Emma Link, PhD, Alexander Dobrovic, H. Miles Prince

Blood (2010) 116 (21): 4046.

https://doi.org/10.1182/blood.V116.21.4046.4046

Published: 2010

Journal Articles

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Hang Quach, MBBS, FRACP, FRCPA, MD, Liam Fernyhough, BMBS, BMediSci, FRACP, FRCPA, Ross Henderson, Gillian Corbett, Kevin Lynch, MBBS, David Ritchie, MBBS, FRACP, FRCPA, PhD, Simon J. Harrison, MD, PhD, H. Miles Prince, MBBS, FRACP, FRCPA, MD

Blood (2010) 116 (21): 1961.

https://doi.org/10.1182/blood.V116.21.1961.1961

Published: 2010

Journal Articles

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Peter Gambell, BSc, MHSM, Neil Came, MBBS, FRACP, FRCPA, Kevin Lynch, MB, BS, FFPM, John F. Seymour, MBBS, PhD, FRACP, Miles Prince, MBBS, MD, MRACMA, FRACP, FRCPA, David A Westerman, MBBS, FRACP, FRCPA

Blood (2009) 114 (22): 2767.

https://doi.org/10.1182/blood.V114.22.2767.2767

Published: 2009

Journal Articles

In Vivo Antagonistic Effects of Dexamethasone On Lenalidomide-Induced NK Cell Activation.

Hang Quach, FRACP, Hsu Andy, MSc, David Ritchie, PhD, Paul Neeson, PhD, Kevin Lynch, MB, BS, Simon Harrison, PhD, Miles Prince, MD

Blood (2009) 114 (22): 1639.

https://doi.org/10.1182/blood.V114.22.1639.1639

Published: 2009

Journal Articles

Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).

Hang Quach, MB, BS, FRACP, FRCPA, David Ritchie, MBChB, FRACP, FRCPA, PhD, Paul Neeson, PhD, Simon Harrison, MB, BS, MRCP, MRCPath, PhD, Tsin Tai, MSc, Kellie Tainton, BSc, Kevin Lynch, MB, BS, FFPM, Miles Prince, MB, BS, FRACP, FRCPA, MRACMA, MD

Blood (2008) 112 (11): 1696.

https://doi.org/10.1182/blood.V112.11.1696.1696

Published: 2008

Journal Articles

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Blood (2008) 112 (10): 3965–3973.

https://doi.org/10.1182/blood-2008-06-161737

Published: 2008

Includes: Supplemental data

Journal Articles

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Susan Branford, Linda Fletcher, Nicholas C. P. Cross, Martin C. Müller, Andreas Hochhaus, Dong-Wook Kim, Jerald P. Radich, Giuseppe Saglio, Fabrizio Pane, Suzanne Kamel-Reid, Y. Lynn Wang, Richard D. Press, Kevin Lynch, Zbigniew Rudzki, John M. Goldman, Timothy Hughes

Blood (2008) 112 (8): 3330–3338.

https://doi.org/10.1182/blood-2008-04-150680

Published: 2008

Journal Articles

Long-term imatinib therapy promotes bone formation in CML patients

Stephen Fitter, Andrea L. Dewar, Panagiota Kostakis, L. Bik To, Timothy P. Hughes, Marion M. Roberts, Kevin Lynch, Barrie Vernon-Roberts, Andrew C. W. Zannettino

Blood (2008) 111 (5): 2538–2547.

https://doi.org/10.1182/blood-2007-07-104281

Published: 2008

Includes: Supplemental data

Journal Articles

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes

Blood (2007) 110 (12): 4064–4072.

https://doi.org/10.1182/blood-2007-06-093617

Published: 2007

Includes: Supplemental data

NARROW

XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL)：Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial)

Low Dose Cyclophosphamide in Combination with Elotuzumab - a Novel Immunotherapeutic Strategy for Multiple Myeloma

Cybord-Dara in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Follow up Results from the 16-Bcni-001/Ctrial-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment

Mesenchymal Stromal Cell Sialylation Enhances Immune Suppression in Multiple Myeloma

An Integrative Genomics Approach Uncovers the Basis of Resistance to AZA Therapy in MDS and CMML

Identification of a Prognostic Gene Expression Signature for AZA Response in MDS and CMML Patients

Cord Blood Plasma Enhances Migration of Hematopoietic Stem and Progenitor Cells (HSPC)

Novel Thrombogenic Biomarkers In Patients with Relapsed/Refractory Multiple Myeloma (MM) Treated with Lenalidomide (LEN) and Dexamethasone (Dex) Therapy

TP53 Mutations In Relapsed/Refractory Multiple Myeloma (MM) Treated with Thalidomide (Thal) or Thalidomide Combination Therapy

Lower-Dose Lenalidomide and Dexamethasone Reduces Toxicity without Compromising Efficacy In Patients with Relapsed/Refractory Myeloma, Who Are Aged ≥60 Years or Have Renal Impairment: Planned Interim Results of a Prospective Multicentre Phase II Trial

Utility of Flow Cytometry (FC) in the Assessment of Therapeutic Efficacy in Myelodysplastic Syndromes (MDS) After Therapeutic Intervention.

In Vivo Antagonistic Effects of Dexamethasone On Lenalidomide-Induced NK Cell Activation.

Regulatory T Cells (Treg) Are Depressed in Patients with Relapsed/Refractory Multiple Myeloma (MM) and Increases towards Normal Range in Responding Patients Treated with Lenalidomide (LEN).

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Long-term imatinib therapy promotes bone formation in CML patients

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only